WEST						
	Help	Logo	ut	Interrupt		
Main Men	u Search Form Posting Cou	ints Show S I	Numbers	Edit S Numbers	Preferences	Cases
		Search 1 Terms L2 and cance	Docu			
US Patents Full-Text Database US Pre-Grant Publication Full-Text Database JPO Abstracts Database EPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins ▼						
Search:	L3			Refine	Search	
	Recall Text	Clear				
Search History						
DATE: Wednesday, March 13, 2002 Printable Copy Create Case						
Set Name side by side Hit Count Set Name result set						
DB=USI	PT; PLUR=YES; OP=ADJ					
<u>L3</u>	L2 and cancer	6	<u>L3</u>			
<u>L2</u>	L1 and erythropoietin	20	<u>L2</u>			

73

<u>L1</u>

END OF SEARCH HISTORY

anagnostou or sigounas

<u>L1</u>

L1

L2

L3

L4

L5

L6

(FILE 'HOME' ENTERED AT 06:42:08 ON 13 MAR 2002)

INDEX 'ADISALERTS, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 06:42:24 ON 13 MAR 2002

SEA ERYTHROPOIETIN (25W) (CANCER OR TUMOR OR TUMOUR) AND TREAT?

```
14
      FILE ADISALERTS
 2
      FILE ADISINSIGHT
      FILE ADISNEWS
  8
      FILE BIOBUSINESS
 3
      FILE BIOCOMMERCE
  4
138
      FILE BIOSIS
      FILE BIOTECHABS
12
      FILE BIOTECHDS
12
127
      FILE BIOTECHNO
179
      FILE CANCERLIT
110
      FILE CAPLUS
      FILE CEABA-VTB
 3
      FILE CIN
11
      FILE CONFSCI
  6
 1
      FILE DDFB
```

- 98 FILE DDFU
- 65 FILE DGENE
- 1 FILE DRUGB
- 4 FILE DRUGNL
- 141 FILE DRUGU
 - 4 FILE DRUGUPDATES
 - 2 FILE EMBAL
- 168 FILE EMBASE
- 69 FILE ESBIOBASE
- 5 FILE IFIPAT
- 17 FILE JICST-EPLUS
- 8 FILE LIFESCI
- 158 FILE MEDLINE
 - 1 FILE NIOSHTIC
- 93 FILE PASCAL
- 2 FILE PHAR
- 11 FILE PHIN
- 56 FILE PROMT
- 130 FILE SCISEARCH
- 111 FILE TOXCENTER
- 69 FILE TOXLIT
- 275 FILE USPATFULL
- 33 FILE WPIDS
- 33 FILE WPINDEX

QUE ERYTHROPOIETIN (25W) (CANCER OR TUMOR OR TUMOUR) AND TREAT?

FILE 'USPATFULL, CANCERLIT, EMBASE, MEDLINE, DRUGU, BIOSIS, SCISEARCH, BIOTECHNO, TOXCENTER, CAPLUS, PASCAL, ESBIOBASE, TOXLIT, DGENE, PROMT, WPIDS, JICST-EPLUS, ADISALERTS, BIOTECHDS, CIN, PHIN, ADISNEWS, LIFESCI, CONFSCI, IFIPAT, BIOCOMMERCE, DRUGNL, ...' ENTERED AT 06:45:05 ON 13 MAR 2002

- 1598 S ERYTHROPOIETIN (15W) (CANCER OR TUMOR OR TUMOUR) AND TREAT?
 773 S L2 AND ERYTHROPOIETIN (15W) (TREAT? OR MODUL? OR ADMINIS?)
- 384 DUP REM L3 (389 DUPLICATES REMOVED)
 - 2 S (ANAGNOSTOU OR SIGOUNAS) AND ERYTHROPOIETIN
 - 2 DUP REM L5 (0 DUPLICATES REMOVED)

L8L9

INDEX 'ADISALERTS, ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOSIS, BIOTECHABS, BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI, CROPB, CROPU, DDFB, DDFU, DGENE, DRUGB, DRUGLAUNCH, DRUGMONOG2, ...' ENTERED AT 07:36:51 ON 13 MAR 2002

SEA RECOMBINANT HUMAN ERYTHROPOIETIN IN THE TREATMENT OF ANEMIA

28 FILE BIOSIS

0* FILE BIOTECHABS

FILE 'BIOSIS' ENTERED AT 07:42:28 ON 13 MAR 2002

28 S RECOMBINANT HUMAN ERYTHROPOIETIN IN THE TREATMENT OF ANEMIA

28 DUP REM L8 (0 DUPLICATES REMOVED)

```
L4 ANSWER 4 OF 5 DRUGU COPYRIGHT 2004 THOMSON DERWENT ON STN DUPLICATE 3
```

AN 1995-07226 DRUGU T S

- TI Phase IV evaluation of clinical outcomes of **Procrit** (Epoetin alfa) in anemic cancer patients receiving chemotherapy.
- AU Bukowski R; Glaspy J; Steinberg D; Taylor C W; Vadhan Raj S; Danna R P; Sarokhan B; Lonczak L; McNeill M
- CS Cleveland-Found.; Univ.Southern-California; Harvard-Med.Sch.; Arizona-Cancer-Cent.; M.D.Anderson-Cancer-Cent.; Ortho-Biotech.

LO USA

- SO Blood (84, No. 10, Suppl. 1, 129a, 1994) 2 Tab. CODEN: BLOOAW ISSN: 0006-4971
- AV The Cleveland Clinic Foundation, Cleveland, OH, U.S.A.
- LA English
- DT Journal
- FA AB; LA; CT
- FS Literature
- S.c. Procrit (epoetin-alpha, human erythropoeitin) reduced the number of patients requiring blood transfusions in a phase IV study involving 2030 cancer patients with anemia treated with chemotherapy regimens containing cisplatin, carboplatin or non-platinum drugs. Energy level, activity level and overall quality of life improved after Procrit therapy. The improvement in quality of life parameters correlated directly with change in Hb from baseline. Procrit was well tolerated. 22% Patients withdrew due to intercurrent illness, adverse events, or death. This study confirmed the results of previously conducted controlled clinical trials. As before, Procrit -treated anemic cancer patients experienced improved energy level, activity level and overall well-being. In addition, transfusion requirements were reduced and Hb was increased. (conference abstract).
- 2030 Patients with various tumor types including hematologic ABEX Methods (23%) and non-hematologic (77%) who were receiving concomitant chemotherapy regimens cisplatin (n = 441), carboplatin (n = 355), non-platinum (n = 1224) and none (n = 10) were treated with s.c. Procrit (150 U/kg 3 times/wk). If the response was not satisfactory after 8 wk of therapy, the dose was increased up to 300 u/kg 3 times/wk for a total treatment duration of up to 4 mth. Results Energy level, activity level and overall quality of life improved (38%, 32%, 24% improvement, respectively). The improvement in quality of life parameters correlated directly with change (1.7 g/dl) in Hb from baseline. During the 4 mth period prior to study start, 37% of the patients required transfusions. At the completion of the 4 mth study with **Procrit** therapy, only 10% of the patients required transfusions. Of those patients who required a transfusion at baseline, 58% became transfusion independent after the 1st mth of the study. 57% Of the patients did not require a transfusion at any time (baseline through termination) during the study. Of the 2030 patients, 59% completed the 4 mth study or achieved an increase in Hb prior to study end, while 22% were discontinued due to intercurrent illness, adverse events, or death (none of the deaths were reported to be drug related) and 19% for other reasons. (Y161/ECB)

- L4 ANSWER 376 OF 384 TOXCENTER COPYRIGHT 2002 ACS
- AN 1992:64760 TOXCENTER
- CP Copyright 2002 BIOSIS
- DN BA93:19497
- TI TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA WITH RECOMBINANT HUMAN ERYTHROPOIETIN IN CANCER PATIENTS
- AU PLATANIAS L C; MILLER C B; MICK R; HART R D; OZER H; MCEVILLY J-M; JONES R J; RATAIN M J
- CS DEP. MED., BOX 420 UNIVERSITY CHICAGO, 5841 S. MARYLAND AVE., CHICAGO ILL,
- SO J CLIN ONCOL, (1991) 9 (11), 2021-2026 CODEN: JCONDN. ISSN: 0732-183X.
- FS BIOSIS
- OS BIOSIS 1992:30222
- LA English
- ED Entered STN: 20011116 Last Updated on STN: 20011116
- AB Thirty patients with chemotherapy-induced anemia were treated with recombinant human erythropoietin for 4 weeks. In this dose-escalation study, cohorts of five to eight patients were treated per dose level. The doses of erythropoietin were 25, 50, 100, 200, or 300 IU/kg/d given intravenously for 5 days each week. Of 30 patients, 15 (50%) had a greater than 10% increase of their hemoglobin (Hb) values and were considered responders. At the two highest dosae levels, 11 of 13 patients (85%) responded. In the 15 responding patients, the mean Hb level increased by 1.7 g/dL from baseline compared with an average decrease of 1.5 g/dL in the previous cycles of chemotherapy without erythropoietin administration.

 Recombinant human erythropoietin is effective in ameliorating chemotherapy-induced anemia when administered in adequate doses.
- TI TREATMENT OF CHEMOTHERAPY-INDUCED ANEMIA WITH RECOMBINANT HUMAN ERYTHROPOIETIN IN CANCER PATIENTS
- AB Thirty patients with chemotherapy-induced anemia were treated with recombinant human erythropoietin for 4 weeks. In this dose-escalation study, cohorts of five to eight patients were treated per dose level. The doses of erythropoietin were 25, 50, 100, 200, or 300 IU/kg/d given intravenously for 5 days. . . by 1.7 g/dL from baseline compared with an average decrease of 1.5 g/dL in the previous cycles of chemotherapy without erythropoietin administration. Recombinant human erythropoietin is effective in ameliorating chemotherapy-induced anemia when administered in adequate doses.

=> d 14 370 bib ab kwic

- L4 ANSWER 370 OF 384 BIOCOMMERCE COPYRIGHT 2002 BioCommerce Data Ltd.
- AN 0020947 BIOCOMMERCE FS Abstract
- CO Imperial Chemical Industries (ICI) Ltd (98), UK
 Churchill Hospital, The (4245), UK
 Royal Postgraduate Medical School (RPMS) (2148), UK
 Christie Hospital & Holt Radium Institute (6906), UK
 Paterson Laboratories (4585), UK
 Imperial Chemical Industries plc (ICI) (18589), UK
 Christie Hospital NHS Trust (27579), UK
 Imperial College School of Medicine (ICSM) (47061), UK
- SO Nursing Times, 24 JUN 1987, vol. 8325, Page(s) 22-23.
- TC General Review
- AB Review of research on growth factors including interleukin- 2 (IL-2), granulocyte colony stimulating factor (G-CSF), epidermal growth factor (EGF) and erythropoietin (EPO) for treating anaemia, cancer and burns.
- AB. . . Review of research on growth factors including interleukin- 2